Trivarx Limited · ASX:TRI
Trivarx — Investor Presentation (November 2023)
18 slides from Trivarx's investor presentation, Nov 16, 2023
Slide 1: Commercialising AI-driven solutions to objectively screen for mental health conditions
For personal use only Commercialising AI-driven solutions to objectively screen for mental health conditions November 2023 (ASX: TRI) Authorised for release by the Board of TrivarX Limited
Slide 2: Forward looking statements
Forward looking statements For personal use only The purpose of the presentation is to provide an update of the business of TrivarX Limited (ASX: TRI). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Ac
Slide 3: A US-based medical technology company
A US-based medical Commercialising AI-driven, evidence based screening products and diagnostic technology company tools to assist in the screening and long-term monitoring of mood disorders For personal use only Research is focused on the robust bidirectional relationship between mental illness and
Slide 4: Major market opportunity and drivers
Major market opportunity and drivers US sleep clinic market growth: Sleep disorders in the US: Correlation between depression and For personal use only sleep disorders: + US$15.92Bn 60m people suffer from poor sleep 75% of people with diagnosed quality depression suffer from disrupted sleep Market v
Slide 5: Innovative solutions
Innovative solutions For personal use only Stager MEB-001 - AI-based software solution that provides researchers - A medical device to screen sleep study patients for the with new data metrics in sleep studies mood disorders - Insights on the 4 key sleep stages in 30 minutes – - Uses Biometric Data,
Slide 6: Stager
Stager A disruptive sleep research tool aimed at the burgeoning US sleep research industry For personal use only Deploys AI, machine learning technology and deep learning algorithms – product aimed at sleep research organisations across the US Identifies the four important sleep stages of a subject;
Slide 7: Stager's unique features and benefits
Stager’s unique features and benefits Speed: Accuracy: For personal use only Human rated sleep scoring takes two or more Stager has been shown to have similar accuracy hours while Stager sleep scoring and HRV to human raters (current gold standard) calculation only takes 30 minutes - Up to 100 files
Slide 8: MEB-001
MEB-001 Potential to become the first FDA approved medical device to screen and monitor for Current Major Depressive Episode (cMDE) using objective data from in-clinic sleep studies For personal use only Only 1.4% of all adult outpatient care visits in the US are screened for depression – MEB-001 ai
Slide 9: Clinical research and technology
Clinical research and technology Supervised Artificial Intelligence For personal use only Clinical Data has been taken from 400+ subjects to date: Clinical Study SLEEP SADB SAMDE PI SAMDE PII Validation Status Complete Complete Complete Underway Planned - Prospective data collection – remains ongoin
Slide 10: MEB-001 – Promising Phase 1 trial results
MEB-001 – Promising Phase 1 trial results - Sleep Signal Analysis of Depression Burden (SAMDE) Study Phase 1 clinical trial completed in July 2023 For personal use only - Aim of SAMDE Phase 1 trial was to detect the likelihood of a current major depressive episode (cMDE) in individuals referred to s
Slide 11: Phase 2 SAMDE trial underway
Phase 2 SAMDE trial underway - Phase 2 trial aims to detect likelihood of a cMDE using Clinician Reporting Outcomes (CRO) assessment in individuals referred to a sleep clinical for PSG assessment using TRI’s algorithm For personal use only - Phase 2 to test up to 400 participants from 14 US sleep ce
Slide 12: Commercial adoption strategies for MEB's solutions
Commercial adoption strategies for MEB’s solutions Licencing opportunities: For personal use only - Initial focus to distribute Stager technology on a SaaS licencing model to research groups - Discussions with target groups underway and agreements anticipated H2 CY2023 - Estimated US sleep research
Slide 13: Investment summary
Investment A scientifically based product portfolio with a defined commercialisation pathway summary and an established regulatory route via the US FDA For personal use only Targeting major market opportunities in the US, in need of innovation and a solution to undiagnosed and misdiagnosed mental he
Slide 14: Contact
Contact Contact TrivarX Limited (ASX: TRI) For personal use only E: Investors@trivarx.com A: 647 Beaufort Street, Mt Lawley, WA 6050 Henry Jordan – Six Degrees Investor Relations T: +61 431 271 538 E: Henry.Jordan@sdir.com.au 14
Slide 15: Appendix 1: Corporate overview
Appendix 1: Corporate overview Corporate snapshot Share price and volume* (Nov 2022 – Nov 2023) For personal use only ASX code: TRI Shares on issue: ~335.7m Market capitalisation (at $0.03 per share): ~$10.1m (as at 9 November 2023) Options on issue: ~170.8m Cash at bank: ~$1.63m Debt: Nil Board and
Slide 16: Appendix 2: Intellectual Property and patents
Appendix 2: Intellectual Property and patents Four patents granted and currently active For personal use only 1 2 US Pat. No. 10,912,508 - Issued 09 Feb 2021. US Pat. No. 10,638,965 - Issued 05 May 2020. Method and system for assessing mental state Method and system for monitoring stress conditions.
Slide 17: Appendix 3: Accomplished Board and management
Appendix 3: Accomplished Board and management Board of Directors: Management: For personal use only David Trimboli – Non-Executive Chairman Archie Defillo – Chief Medical Officer - Founder of Seefeld investments, an Australian-based investment firm - 25 years clinical experience with neurological di
Slide 18: Appendix 4: Citations
Appendix 4: Citations Projected Growth: $9.20B/2021 to $15.92B/2028 with CAGR of 8.2%: For personal use only https://www.fortunebusinessinsights.com/u-s-sleep-disorder-clinics-market-106600 Just 1.4% depression screening rate for all adult outpatient care visits: appi.ps.201700439 (psychiatryonline.